Evidence map›Paper›PMID 39891834›Full record

Observational studyAIDS and behavior2025

Experiences and Preferences in Zambia and South Africa for Delivery of HIV Treatment During a Client's First Six Months: Results of the PREFER Study's Cross-Sectional Baseline Survey.

Nyasha Mutanda, Allison Morgan, Aniset Kamanga, Linda Sande, Vinolia Ntjikelane, Mhairi Maskew, Prudence Haimbe, Priscilla Lumano-Mulenga, Sydney Rosen, Nancy Scott

2 registry-linked trialsAbstract readObservational Study
In one paragraph

Observational study in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05454839 active not recruitingnot on this map

Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa

TypeobservationalSponsorBoston UniversityRan2022 to 2026Enrolled1,098ConditionsHIVArmsSurvey, Focus group
NCT05454852 active not recruitingnot on this map

Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in Zambia

TypeobservationalSponsorBoston UniversityRan2022 to 2026Enrolled771ConditionsHIVArmsSurvey, Focus group
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nyasha MutandaHealth Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-2464-5124
Allison MorganDepartment of Global Health, Boston University School of Public Health, Boston, USA.ORCID http://orcid.org/0000-0001-8877-5107
Aniset KamangaClinton Health Access Initiative-Zambia, Lusaka, Zambia.ORCID http://orcid.org/0000-0003-2994-2459
Linda SandeHealth Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0009-0003-4230-5961
Vinolia NtjikelaneHealth Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Mhairi MaskewHealth Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-4238-0200
Prudence HaimbeClinton Health Access Initiative-Zambia, Lusaka, Zambia.
Priscilla Lumano-MulengaMinistry of Health, Lusaka, Zambia.
Sydney Rosen *Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-6560-2964
Nancy Scott *Department of Global Health, Boston University School of Public Health, Boston, USA. nscott@bu.edu.ORCID http://orcid.org/0000-0002-4713-4642

Funding

Gates Foundation INV-031690
6 · The paper itself

Abstract

Disengagement from antiretroviral therapy (ART) is highest in the early treatment period (≤ 6 months after initiation/re-initiation), but low intensity models designed to increase retention generally exclude these clients. We describe client preferences for HIV service delivery in the early treatment period. From 9/2022 to 6/2023, we surveyed adult clients who were initiating or on ART for ≤ 6 months at primary health facilities in South Africa and Zambia. We collected data on experiences with and preferences for HIV treatment. We enrolled 1,098 participants in South Africa (72% female, median age 33) and 771 in Zambia (67% female, median age 32), 38% and 34% of whom were initiating/re-initiating ART in each country, respectively. While clients expressed varied preferences, most participants (94% in South Africa, 87% in Zambia) were not offered choices regarding service delivery. 82% of participants in South Africa and 36% in Zambia reported receiving a 1-month supply of medication at their most recent visit; however, South African participants preferred 2- or 3-month dispensing (69%), while Zambian participants preferred 3-or 6-month dispensing (85%). Many South African participants (65%) would prefer to collect medication in community settings, while Zambian participants (70%) preferred clinic-based collection. Half of participants desired more one-on-one counselling and health information. Most participants reported positive experiences with providers, but long waiting queues were reported by South African participants.During the first six months on ART, many clients would prefer less frequent clinic visits, longer dispensing intervals, and frequent, high-quality counselling. Care models for the early treatment period should reflect these preferences.Registration: Clinicaltrials.gov NCT05454839, Clinicaltrials.gov NCT05454852.

Indexed as

Anti-HIV AgentsDelivery of Health CareHIV InfectionsPatient PreferenceAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrimary Health CareSouth AfricaSurveys and QuestionnairesYoung AdultZambiaAnti-HIV AgentsAntiretroviral treatmentClient-centered careEarly treatment periodHIVPreferencesSouth AfricaZambia

Identifiers

PMID39891834
PMCPMC12075270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.